Effect of Anti‐ IL ‐23 and Anti‐ IL ‐17 Therapy on Darier Disease: A Case Series
Australasian Journal of Dermatology · 2026-11 · 67 (7) · 414-419
DOI: 10.1111/ajd.70155 ↗Abstract
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater improvement in disease severity and patient‐reported outcomes and no reported adverse events. Although limited by the small sample size and attrition over time, these findings support further prospective evaluation of biologic therapies in Darier disease.
EUVIMED